

# Brian Befano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8911182/publications.pdf>

Version: 2024-02-01

29  
papers

1,517  
citations

471509

17  
h-index

477307

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1710  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2019, 111, 923-932.	6.3	249
2	A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia. <i>Cancer Research</i> , 2010, 70, 3159-3169.	0.9	221
3	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. <i>Journal of the National Cancer Institute</i> , 2018, 110, 501-508.	6.3	116
4	Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 132-143.	1.9	116
5	A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. <i>EClinicalMedicine</i> , 2020, 22, 100293.	7.1	109
6	Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2010, 340, c712-c712.	2.3	78
7	A cohort study of cervical screening using partial HPV typing and cytology triage. <i>International Journal of Cancer</i> , 2016, 139, 2606-2615.	5.1	68
8	Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1184-1191.	1.6	65
9	Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 261-267.	1.9	55
10	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. <i>Gynecologic Oncology</i> , 2015, 138, 573-578.	1.4	49
11	A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 144-147.	1.9	48
12	Why does cervical cancer occur in a state-of-the-art screening program?. <i>Gynecologic Oncology</i> , 2017, 146, 546-553.	1.4	47
13	A demonstration of automated visual evaluation of cervical images taken with a smartphone camera. <i>International Journal of Cancer</i> , 2020, 147, 2416-2423.	5.1	46
14	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1304-1310.	2.5	44
15	Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention. <i>International Journal of Cancer</i> , 2020, 147, 2677-2686.	5.1	44
16	The development of "automated visual evaluation" for cervical cancer screening: The promise and challenges in adapting deep learning for clinical testing. <i>International Journal of Cancer</i> , 2022, 150, 741-752.	5.1	29
17	Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. <i>Journal of Infectious Diseases</i> , 2016, 213, 939-947.	4.0	18
18	Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	18

#	ARTICLE	IF	CITATIONS
19	Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. <i>Vaccine</i> , 2015, 33, 2141-2151.	3.8	17
20	A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California. <i>International Journal of Cancer</i> , 2020, 147, 1612-1620.	5.1	15
21	Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1222-1228.	6.3	12
22	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. <i>Journal of the National Cancer Institute</i> , 2022, 114, 845-853.	6.3	12
23	Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2348-2355.	3.9	10
24	Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus-Positive Screening Test Results. <i>Journal of Lower Genital Tract Disease</i> , 2022, 26, 127-134.	1.9	9
25	Network Visualization and Pyramidal Feature Comparison for Ablative Treatability Classification Using Digitized Cervix Images. <i>Journal of Clinical Medicine</i> , 2021, 10, 953.	2.4	7
26	Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 97-103.	1.9	5
27	Different human papillomavirus types share early natural history transitions in immunocompetent women. <i>International Journal of Cancer</i> , 2022, 151, 920-929.	5.1	5
28	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0865.2021.	2.5	3
29	Development of a Large Biorepository of Cervical Specimens for the Improving Risk Informed HPV Screening Study (IRIS). <i>Journal of Clinical Virology</i> , 2021, 145, 105014.	3.1	2